Ameriprise
AUTL

Ameriprise’s Autolus Therapeutics AUTL Stock Holding History

Ameriprise’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16,692
Closed -$106K – 3867
2024
Q1 		$106K Buy
+16,692
New +$104K ﹤0.01% 3776
2022
Q1 		– Sell
-21,864
Closed -$114K – 3938
2021
Q4 		$114K Buy
21,864
+7,361
+51% +$44.2K ﹤0.01% 3863
2021
Q3 		$95K Buy
+14,503
New +$91.6K ﹤0.01% 3783

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ameriprise's AUTL Position: Q2 2024 in Review

Ameriprise sold out of Autolus Therapeutics (AUTL) in Q2 2024, closing a stake of 16,692 shares — an estimated $106K sold.

Ameriprise first reported a position in AUTL in Q3 2021 and held it in 3 quarters. The position peaked at $114K in Q4 2021. 111 funds tracked by Wall St. Rank hold AUTL as of Q2 2024.

  • Ameriprise reported no remaining Autolus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Ameriprise sold 16,692 Autolus Therapeutics shares in Q2 2024, an estimated $106K.
  • Ameriprise first reported a position in Autolus Therapeutics in Q3 2021 and held it in 3 quarters.
  • Ameriprise's Autolus Therapeutics position peaked at $114K in Q4 2021.
  • 111 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2024.

Based on Ameriprise's 13F filing for Q2 2024, filed 14 Aug 2024.